AU2001254812A1 - 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations - Google Patents

9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations

Info

Publication number
AU2001254812A1
AU2001254812A1 AU2001254812A AU5481201A AU2001254812A1 AU 2001254812 A1 AU2001254812 A1 AU 2001254812A1 AU 2001254812 A AU2001254812 A AU 2001254812A AU 5481201 A AU5481201 A AU 5481201A AU 2001254812 A1 AU2001254812 A1 AU 2001254812A1
Authority
AU
Australia
Prior art keywords
oxa
production
pharmaceutical preparations
epothilon
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001254812A
Inventor
Bernd Buchmann
Jens Hoffmann
Ulrich Klar
Rosemarie Lichtner
Wolfgang Schwede
Werner Skuballa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU2001254812A1 publication Critical patent/AU2001254812A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2001254812A 2000-04-20 2001-04-19 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations Abandoned AU2001254812A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10020899A DE10020899A1 (en) 2000-04-20 2000-04-20 New 9-oxa-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease
DE10020899 2000-04-20
PCT/EP2001/004551 WO2001081341A2 (en) 2000-04-20 2001-04-19 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations

Publications (1)

Publication Number Publication Date
AU2001254812A1 true AU2001254812A1 (en) 2001-11-07

Family

ID=7640245

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001254812A Abandoned AU2001254812A1 (en) 2000-04-20 2001-04-19 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations

Country Status (7)

Country Link
US (1) US20030139460A1 (en)
EP (1) EP1282618A2 (en)
JP (1) JP2003531206A (en)
AU (1) AU2001254812A1 (en)
DE (1) DE10020899A1 (en)
NO (1) NO20025028D0 (en)
WO (1) WO2001081341A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6706931B2 (en) 2000-12-21 2004-03-16 Shell Oil Company Branched primary alcohol compositions and derivatives thereof
DE60333754D1 (en) * 2002-06-10 2010-09-23 Novartis Ag EPOTHILONE CONTAINING COMBINATIONS AND THEIR PHARMACEUTICAL USES
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4791183B2 (en) 2002-08-23 2011-10-12 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ Synthesis and use of epothilone, its intermediates and analogues
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
IL144519A0 (en) * 1999-02-18 2002-05-23 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
DE19908765A1 (en) * 1999-02-18 2000-08-24 Schering Ag New, chemically and metabolically stable 16-halo or cyano-epothilone derivatives are cell division regulators useful e.g. for treating malignant tumors or chronic inflammatory disease
PE20010116A1 (en) * 1999-04-30 2001-02-15 Schering Ag 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTILONE DERIVATIVES, PROCEDURES FOR THEIR PREPARATION
DE19921086A1 (en) * 1999-04-30 2000-11-02 Schering Ag New stable 6-alkenyl- or 6-alkynyl-epothilone derivatives, are cell division regulators useful for treating malignant tumors, angiogenesis or chronic inflammatory disease

Also Published As

Publication number Publication date
NO20025028L (en) 2002-10-18
DE10020899A1 (en) 2001-10-25
NO20025028D0 (en) 2002-10-18
WO2001081341A2 (en) 2001-11-01
US20030139460A1 (en) 2003-07-24
JP2003531206A (en) 2003-10-21
WO2001081341A3 (en) 2002-04-25
EP1282618A2 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
ZA200109859B (en) 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations.
HUP0201711A3 (en) N-indanyl-benzamide derivatives, method for their production, their use and pharmaceutical preparations containing them
PL349863A1 (en) 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
AU2002225356A1 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
AU2001262221A1 (en) Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use
HUP0302295A3 (en) Thienodibenzoazulene derivatives, process for their preparation and use thereof
AU3156600A (en) Novel epothilon derivatives, method for the production thereof and their pharmaceutical application
AU3301700A (en) (n)-sulfonyl-dipeptide derivatives, production and use thereof in therapy
AU2000254308A1 (en) Pyrazolopyrimidinone derivatives, process for their preparation and their use
AU2001254812A1 (en) 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations
IL145041A (en) Morpholine derivatives, methods for the production thereof and pharmaceutical preparations
AU2002227966A1 (en) Coniosetin and derivatives thereof, method for producing the same and use thereof
AU2001252671A1 (en) Pyridobenzodiazine derivatives and processes for the preparation thereof
AU2002210439A1 (en) Method for producing peptide salts, their use, and pharmaceutical preparations containing these peptide salts
AU2001252254A1 (en) 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparationthereof and use thereof
AU2001260083A1 (en) New pharmaceutical composition and the process for its preparation
AU7517800A (en) 3-vinylpyrrole derivatives, method for the production thereof and their use as medicaments
AU2002227952A1 (en) Klainetin and derivatives thereof, method for their production and the use of the same
IL156160A0 (en) Klainetins and their derivatives, method for their preparation and use thereof
AU2942100A (en) Vitamin d derivatives and process for the preparation thereof
AU2002211034A1 (en) Aziridinylquinolinedione derivatives and process for their preparation
HUP0204393A3 (en) Pluraflavins and derivatives thereof, process for their preparation and use thereof
AU2002217647A1 (en) Pharmaceutical composition, the use thereof and method for producing said composition
AU2001232300A1 (en) 6-substituted-4,5-epoxy-6-hydroxy-2-cyclohexen-1-one derivatives and intermediates in the production thereof
AU2000249111A1 (en) New pharmaceutical composition and the process for its preparation